Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $1.1 million.

  • Artiva Biotherapeutics' Change in Accured Expenses fell 63.93% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year decrease of 384.45%. This contributed to the annual value of -$659,000 for FY2024, which is 27.74% up from last year.
  • As of Q3 2025, Artiva Biotherapeutics' Change in Accured Expenses stood at $1.1 million, which was up 303.45% from -$550,000 recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Change in Accured Expenses ranged from a high of $3.1 million in Q3 2024 and a low of -$3.0 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$359,000 (2023), whereas its average is -$137,444.
  • Data for Artiva Biotherapeutics' Change in Accured Expenses shows a peak YoY increase of 964.07% (in 2024) and a maximum YoY decrease of 793.71% (in 2024) over the last 5 years.
  • Artiva Biotherapeutics' Change in Accured Expenses (Quarterly) stood at $143,000 in 2023, then tumbled by 793.71% to -$992,000 in 2024, then crashed by 63.93% to $1.1 million in 2025.
  • Its Change in Accured Expenses stands at $1.1 million for Q3 2025, versus -$550,000 for Q2 2025 and -$931,000 for Q1 2025.